Exosomal Biomarker Discovery
CellSpring develops minimally invasive tests for diagnosing early stage cancer. The tests rely on discovery of novel, exosomal biomarkers using our proprietary 3D Bloom platform.
Detecting cancer early means catching it before a patient even has symptoms -- when the full gamut of therapeutic options is available.
Daniel Eberli, MD/PhD
Urologist and principal investigator at the University Hospital in Zurich. Prof. Eberli acts as scientific advisor to CellSpring and his lab collaborates with us to drive clinical proof of concept of our prostate cancer biomarkers.
October 2019, Renens, Switzerland: CellSpring won the Platinum Prize at the pitching competition of MassChallenge Switzerland! We were selected after four rounds of judging from an intial pool of over 1'000 applicants. The prize includes a cash award of CHF 80'000.
Oct. 2018, Zurich, Switzerland: USZ lab of Prof. Daniel Eberli awarded a research grant for CellSpring collaboration. The focus of the project is discovery of novel biomarkers for prostate cancer.